What is stromal vascular fraction

Overall, regenerative cell therapy based on SVF is at an early investigative stage but its potential for clinical application is enormous. Keywords: Adipose derived stem cells; Preadipocytes; Progenitor cells; Stem cell regeneration; Stromal vascular fraction. Published by Elsevier Ltd. Adipose-derived stem cells for regenerative medicine.

Circ Res. Colen BD. A pill to shed fat? Accessed 8 Sept White-to-brown metabolic conversion of human adipocytes by JAK inhibition. Nat Cell Biol. Enzymatic and non-enzymatic isolation systems for adipose tissue-derived cells: current state of the art. Cell Regen. Nanofat grafting: basic research and clinical applications.

Mechanical versus enzymatic isolation of stromal vascular fraction cells from adipose tissue. A non-enzymatic method for isolating human adipose tissue-derived stromal stem cells. Part 2: mechanisms of regenerative action. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Multilineage cells from human adipose tissue: implications for cell-based therapies.

Development of a system and method for automated isolation of stromal vascular fraction from adipose tissue lipoaspirate. Stem Cells Int. Critical steps in the isolation and expansion of adipose-derived stem cells for translational therapy.

Expert Rev Mol Med. The role of nanofat grafting in vulvar lichen sclerosus: a preliminary report. Arch Plast Surg. Nanofat grafting under a split-thickness skin graft for problematic wound management. Adv Wound Care. Invitrogen cell data sheet-ADSC. Accessed 7 Sept Sponsored paper. Phenotypic characterization and in vivo localization of human adipose-derived mesenchymal stem cells.

Mol Cells. Concise review: circulating endothelial progenitor cells for vascular medicine. Image analysis of endothelial microstructure and endothelial cell dimensions of human arteries—a preliminary study. Adv Eng Mater. Anatomy atlases: atlas of microscopic anatomy: section 4—blood. Plate 4.

Force microscopy of nonadherent cells: a comparison of leukemia cell deformability. Biophys J. Cell size of alveolar macrophages: an interspecies comparison.

Environ Health Perspect. Duke University Medical School. Histology learning resources. Pericytes support neutrophil subendothelial cell crawling and breaching of venular walls in vivo. J Exp Med. Adipocyte induction of preadipocyte differentiation in a gradient chamber.

Tissue Eng Part C Methods. A population of multipotent CDpositive adipose stromal cells share pericyte and mesenchymal surface markers, reside in a periendothelial location, and stabilize endothelial networks. Robust functional vascular network formation in vivo by cooperation of adipose progenitor and endothelial cells.

Characterisation of angiogenetic growth factor production in adipose tissue-derived mesenchymal cells. J Plast Surg Hand Surg. Content of soluble factors and characteristics of stromal vascular fraction cells in lipoaspirates from different subcutaneous adipose tissue depots.

Aesthetic Surg J. Concise review: therapeutic potential of adipose tissue-derived angiogenic cells. A perivascular origin for mesenchymal stem cells in multiple human organs.

Cell Stem Cell. Native human adipose stromal cells: localization, morphology and phenotype. Int J Obes. Is CD34 truly a negative marker for mesenchymal stromal cells?

Stem Cells Dev. Concise review: evidence for CD34 as a common marker for diverse progenitors. Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. The role of hypoxia in bone marrow-derived mesenchymal stem cells: considerations for regenerative medicine approaches.

Tissue Eng Part B Rev. The effect of hypoxia on mesenchymal stem cell biology. Adv Pharm Bull. Hypoxic preconditioning of mesenchymal stromal cells induces metabolic changes, enhances survival, and promotes cell retention in vivo.

Hypoxic culture conditions as a solution for mesenchymal stem cell based regenerative therapy. Sci World J. Hypoxia enhances proliferation and tissue formation of human mesenchymal stem cells. Biochem Biophys Res Commun. Hypoxia-cultured human adipose-derived mesenchymal stem cells are non-oncogenic and have enhanced viability, motility, and tropism to brain cancer.

Cell Death Dis. After you are positioned on the procedure table, and the skin is cleaned using an antiseptic. After numbing the area using a local anesthetic, the Chicago stem cell doctor makes a small incision at the abdomen or other body area. A small cannula is inserted, and the adipose cells are gently removed via suction.

Once obtained, the solution called lipoaspirate is processed in the operating room, and the incision is closed with Steri-Strips or a Band-Aid. The lipoaspirates fat tissue components removed by aspiration are digested with an enzyme solution, which breaks down the matrix.

The MSCs are released from the tissue. After being processed through centrifugation spinning and dilution, the ASCs are washed and isolated. The cells are processed again times, and the end product is the SVF. In adipose tissue, the number of stem cells derived as SVF can vary. Current researchers have found that most of the injected SVF fluid is reabsorbed within days following the injection.

Adipose derived stem cells attach to the lesion, however, and survive a prolonged amount of time. They have red blood cells, adipocytes, and white blood cells, which work together to heal the treated structure.

Ichim TE, et al. Autologous stromal vascular fraction cells: a tool for facilitating tolerance in rheumatic disease. Cell Immunol, 1 :7— Current use of autologous adipose tissue-derived stromal vascular fraction cells for orthopedic applications.

Journal of Biomedical Science, 24, 9. Riordan NH, et al. There may even be some primitive fibroblasts that are more like progenitor cells. A few fat cells or adipocytes will be there along with some fat cell progenitors called pre-adipocytes. Blood vessel cells will also be in SVF, including endothelial cells and smooth muscle cells. Also in SVF are really interesting cells called pericytes that hug the exterior of blood vessels.

They may have some stem cell like properties, perhaps being able to make smooth muscle cells and a few other types. The National Cancer Institute NCI has its own definition of stromal vascular fraction here , but I think they are a bit generous on their description of the known functional properties.

There are likely to be fragments of many cells in SVF preps too depending on how it is made and purified. Those could pose risks.

Something called lipogems are also made from fat. Here are a few articles in Pubmed on lipogems. There are many fat products out there and some universities and large academic medical centers are starting to do trials on various preps. There has been some back and forth about whether SVF is a natural product. This could have big implications because the real debate here is whether SVF as used by clinics has been more than minimally manipulated aka not natural.

Instead, SVF is a laboratory-manufactured product. It might be helpful here to compare SVF to bone marrow aspirate, which is generally considered minimally manipulated as typically prepared because the marrow cells are basically the same inside the body as they are outside the body in the aspirate that is then injected into patients. Another issue I raised in that post is the question of homologous use of SVF. This means using a product in a way that is similar to the original tissue inside the body.

For instance, homologous use of kidney stem cells would only probably be possible to treat kidney disease. In this sense, SVF could only be used in a homologous manner to treat a disease related to fat, such as facial wasting. From my blog post:. If a product is used in a non-homologous manner e.

SVF being used to treat non-fat-related health conditions like neurological conditions, many orthopedic issues, eye problems, sexual issues, etc. It seems to me at least, that many of the reported applications of SVF are likely to be non-homologous. This post today,July 4, looks like a rerun on this same topic a year ago. One for knee IA and another for rotator cuff tear. There appears to be great potential benefit in these treatments! Paul, great topic and questions.

I am a veterinarian with 35 year contract research experience doing human and veterinary research for FDA submissions.